Immutep Limited Stock Australian S.E.
Stocks
IMMAQ
AU0000281537
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 73.69M 52.02M 45.08M 42.21M 38.51M 72.47M 4.96B 495M 194M 2.48B 195M 191M 8.29B | P/E 2026 * |
-1.29x | P/E 2027 * | -1.84x |
|---|---|---|---|---|---|
| Enterprise Value | 8.69M 6.13M 5.32M 4.98M 4.54M 8.54M 585M 58.35M 22.86M 293M 23.03M 22.53M 977M | EV / Sales 2026 * |
0.5x | EV / Sales 2027 * | -1.11x |
| Free-Float |
96.98% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 2014-07-08 |
David Fang
DFI | Director of Finance/CFO | - | 2018-02-28 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 2014-07-08 |
Russell Howard
CHM | Chairman | 76 | 2017-11-16 |
Pete Meyers
BRD | Director/Board Member | 57 | 2014-02-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 49.98M | |
| -0.72% | +3.41% | +6.32% | +16.27% | 50.03B | |
| -0.69% | +6.25% | +492.36% | +585.40% | 44.36B | |
| +0.08% | +11.23% | +23.99% | +81.74% | 40.82B | |
| +0.76% | +6.85% | +35.40% | +10.92% | 39.83B | |
| +4.73% | +13.29% | +27.76% | +54.22% | 32.51B | |
| -0.41% | +4.08% | - | - | 16.85B | |
| +0.51% | +5.29% | +34.62% | +126.87% | 16.81B | |
| -0.20% | +1.57% | +5.49% | +21.35% | 14.05B | |
| +1.81% | +20.45% | +89.35% | +31.49% | 13.22B | |
| Average | +0.59% | +283.03% | +89.41% | +116.03% | 29.83B | |
| Weighted average by Cap. | +0.53% | +297.81% | +108.45% | +139.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.23M 12.17M 10.54M 9.87M 9.01M 16.95M 1.16B 116M 45.35M 581M 45.68M 44.69M 1.94B | 3.16M 2.23M 1.93M 1.81M 1.65M 3.1M 213M 21.2M 8.31M 106M 8.37M 8.19M 355M |
| Net income | -58.54M -41.33M -35.81M -33.53M -30.59M -57.57M -3.94B -393M -154M -1.97B -155M -152M -6.58B | -47.05M -33.22M -28.79M -26.95M -24.59M -46.27M -3.17B -316M -124M -1.59B -125M -122M -5.29B |
| Net Debt | -65M -45.89M -39.77M -37.23M -33.97M -63.92M -4.38B -437M -171M -2.19B -172M -169M -7.31B | -77.18M -54.49M -47.22M -44.21M -40.34M -75.9M -5.2B -518M -203M -2.6B -205M -200M -8.68B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
